Latest Humira dispute highlights biosimilar trade secrets dangers

AbbVie’s clash with an adalimumab biosimilar producer is the latest in a string of lawsuits showing why biologics originators and imitators need strategies to protect proprietary information

Enter your details below to log into your account.

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Twitter

14 Apr 2021

@IAM_Alerts Today's IAM Long Read - Charting the value of IP and other intangible assets can be difficult, but there are ways o… https://t.co/1vadiAqfo5 Read more

14 Apr 2021

@IAM_Alerts The Long Read: How mapping IP and other intangibles can drive business value https://t.co/XDuY3GyJwf https://t.co/ey5GUz1sZf Read more

14 Apr 2021

@IAM_Alerts How a patent deal with Sharp gave China's top LED makers ammunition against a key rival https://t.co/5bUlgdgz8B https://t.co/1IOAxubqZA Read more

13 Apr 2021

@IAM_Alerts RT @WBD_US: Don't miss Ben Bourke's insights in @IAM_Alerts, as he discusses how #lifescience companies have handled their #IP portfolios o… Read more

Find an expert

Ylva Skoglösa

Partner

Frederiksberg, Denmark

Aera

View full biography

Latest Humira dispute highlights biosimilar trade secrets dangers

Returning user?

Want to read more?

Adam Houldsworth

TAGS

Twitter

Find an expert